News for XXII Stock

22nd Century to Present at the Emerging Growth Conference on May 21, 2025 22nd Century Group Reports First Quarter 2025 Financial Results 22nd Century Group Completes Sale of Needle Rock Farms Assets 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction 22nd Century Group to Announce First Quarter 2025 Results on May 13, 2025 22nd Century Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions 22nd Century Revenue Growth from Continued Expansion of CMO Volume with New Filtered Cigar Agreements 22nd Century CEO & Chairman Larry Firestone Provides Corporate Update Letter to Stockholders 22nd Century Group Reports Fourth Quarter and Full Year 2024 Financial Results  22nd Century Group to Announce Fourth Quarter and Full Year 2024 Results on March 20, 2025 22nd Century Announces First Partner VLN Agreement, New VLN Availability with Smoker Friendly 22nd Century to Present at the Emerging Growth Conference on February 19, 2025 22nd Century Regains Full Compliance with Nasdaq Continued Listing Standards FDA Publishes Proposed New Tobacco Product Standard for Nicotine Yield, Citing VLN from 22nd Century as the Only Combustible Cigarette That Complies with the New Standard Washington Post Story Featuring 22nd Century VLN Products Highlights Proposed FDA Reduced Nicotine Content Policy Could Initially Benefit An Estimated 13 Million Smokers 22nd Century Stands Ready to Support the Adoption of FDA Proposed Tobacco Product Standard to Mandate Reduced Nicotine Content in Cigarettes with its VLN Cigarettes 22nd Century Group Signs New, Expanded License and Manufacturing Agreement with Smoker Friendly 22nd Century Announces 1-for-135 Reverse Stock Split 22nd Century Group Reports Third Quarter 2024 Financial Results 22nd Century Group (XXII) to Announce Third Quarter 2024 Results on November 12, 2024 22nd Century Group to Present at the LD Micro Main Event XVII on October 30 in Los Angeles 22nd Century Regains Compliance with Nasdaq Stockholders' Equity Requirement 22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume 22nd Century Announces New Branded Products Order with Customer for Southeast Asia 22nd Century Updates Strategic Growth Initiatives for VLN 22nd Century Satisfies IP Licensing and Sponsored Research Obligations to NCSU Through 2025 in an Equity Transaction 22nd Century Group to Participate in the HC Wainwright Conference on September 10, 2024 22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility 22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024 22nd Century Group Reports Second Quarter 2024 Financial Results 22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024 22nd Century Appoints Robert Manfredonia as Executive Vice President of Sales and Marketing 22nd Century Announces New Greenbutts Manufacturing Agreement for Innovative Plant-Based, Biodegradable Cigarette Filters 22nd Century to Re-Launch and Expand VLN(R) Presence in South Korea 22nd Century Group to Participate in the Emerging Growth Virtual Conference on July 17, 2024 22nd Century Reduces Debt by Additional $1.5 Million via Payment from GVB 22nd Century Announces Resignation of John Miller as President of Tobacco 22nd Century Group Reports First Quarter 2024 Financial Results 22nd Century Eliminates an Additional $2.3 Million of Debt 22nd Century Group to Participate in the Aegis Capital Virtual Conference on May 9, 2024 22nd Century Group (XXII) to Announce First Quarter 2024 Results on May 15, 2024 22nd Century Eliminates $5.2 Million of Debt in Above-Market Equity Transaction 22nd Century Group Announces Resignation of Sullivan and Mish from the Board of Directors 22nd Century Group Regains Compliance with NASDAQ Minimum Bid Price Rule 22nd Century Group to Participate in the Planet MicroCap Showcase on May 1-2, 2024 22nd Century Group Expands CMO Business with New Pinnacle Brand Cigarillo Products 22nd Century Announces Plan to Eliminate Its Senior Secured Debt 22nd Century Group (XXII) Signs Large New CMO Customer 22nd Century Group (XXII) Reports Fourth Quarter 2023 Financial Results 22nd Century Group to Announce Fourth Quarter 2023 Results on March 28, 2024 22nd Century Group Announces Reduction in Board Compensation 22nd Century Group to Present at the Emerging Growth Conference on February 8, 2024 22nd Century Group Announces Partial Adjournment of Annual Meeting for Proposal 2, All Other Proposals Passed 22nd Century Group Provides Shareholder Update and Highlights Insider Stock Purchases from Management 22nd Century Group to Host Fireside Chat Event on January 17 22nd Century Group Completes Sale of Hemp/Cannabis Franchise 22nd Century Group's Senior Lender Approves Sale of Hemp/Cannabis Franchise on Improved Terms 22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction 22nd Century Appoints Larry Firestone as Chairman and CEO 22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise 22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores 22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License 22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results 22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB 22nd Century Group (XXII) Reduces Debt by $8.1 Million 22nd Century Announces Pricing of $5.25 Million Public Offering 22nd Century Announces Proposed Public Offering 22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States 22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets 22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results 22nd Century Group (XXII) Updates Second Quarter 2023 Results Webcast Time on August 14, 2023 22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023 22nd Century Announces Executive Leadership Changes 22nd Century Group (XXII) Regains Compliance with Nasdaq Listing Standards A Cigarette to Help Californians Smoke Less: 22nd Century Group, Inc. Launches Reduced Nicotine VLN® King Cigarettes in California, VLN Will Be Sold at #1 U.S. Convenience Store Chain and Other Responsible Retail Locations New to The Street TV Announces Episode 488 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Tonight, July 13, 2023, at 9:30 PM PT 22nd Century Group (XXII) VLN® Products Now Selling in Montana C-Stores 22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution 22nd Century Announces $3.0 Million Registered Direct Offering Priced Above Market 22nd Century Announces 1-for-15 Reverse Stock Split 22nd Century Group (XXII) Announces Production of VLN® Homogenized Tobacco Leaf Sheet VLN® Products Launch in Nevada to Help Smokers Smoke Less 22nd Century Announces $5.3 Million Registered Direct Offering Priced Above Market 22nd Century Group (XXII) Launching VLN® at #1 U.S. C-Store Chain in Texas, California and Florida 22nd Century Group (XXII) Announces Participation in the LD Micro Invitational XIII 22nd Century Group (XXII) Highlights Recent TCORS Symposium Findings 22nd Century Group (Nasdaq: XXII) Reports First Quarter 2023 Financial Results, Introduces 2023 Full Year Revenue Outlook 22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2023 Results on May 9, 2023 22nd Century Group (XXII) Announces Strategic License, Manufacturing and Distribution Agreement with Old Pal 22nd Century Group (XXII) Announces Fully Integrated, Single-Source Strategic License, Manufacturing and Distribution Agreement with Cookies 22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update 22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives 22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference 22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023 22nd Century Group (XXII) Accelerates Major Growing Program to Enable Implementation of New Zealand’s Reduced-Nicotine Content Tobacco Law Nearly Three Out of Four Colorado Smokers Want to Quit and Now Have a New Option That “Helps You Smoke Less”   22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position 22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs 22nd Century Group’s GVB Biopharma Opens New Central Distribution Facility in The Netherlands 22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas 22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences 22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022 New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation 22nd Century Group (Nasdaq: XXII) to Announce Third Quarter 2022 Results on November 8, 2022 22nd Century Group (Nasdaq: XXII) to Expand VLN® Sales in Three Additional States: Arizona, Utah and New Mexico 22nd Century Group (Nasdaq: XXII) to Present at LD Micro Conference on October 26 22nd Century Group (Nasdaq: XXII) to Participate in the Dawson James Small Cap Growth Conference on October 12 First Cigarette Authorized by FDA to “Help You Smoke Less” Now Available Across Colorado 22nd Century Group (Nasdaq: XXII) Expands VLN® Distributor Network with the Addition of Specialty Distributor Creager Mercantile 22nd Century Group (Nasdaq: XXII) Partners With Eagle Rock Distributing Company to Place VLN® in Thousands of Retail Locations Across Colorado 22nd Century Group’s (Nasdaq: XXII) VLN® Cigarettes with Reduced Nicotine Technology Ready to Ignite Biden’s Cancer Moonshot Initiative 22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board 22nd Century Group (Nasdaq: XXII) Announces Management Updates and Departure of Chief Operating Officer 22nd Century Group (Nasdaq: XXII) Launches VLN® Reduced Nicotine Content Cigarettes in Colorado with Circle K, Smoker Friendly and New Distribution Points 22nd Century Group (Nasdaq: XXII) VLN® Reduced Nicotine Content Cigarettes Awarded Best New Product by Convenience Store News 22nd Century Group (Nasdaq: XXII) to Ring the Nasdaq Stock Market Closing Bell 22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Second Quarter 2022 22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2022 Results on August 9, 2022 22nd Century Group (Nasdaq: XXII) Strengthens Balance Sheet to Accelerate the Expansion of VLN Launch 22nd Century Announces $35 Million Registered Direct Offering Priced Above Market under Nasdaq Rules 22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require Less Nicotine in All U.S. Cigarettes 22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO 22nd Century Group (Nasdaq: XXII) to Participate in LD Micro, Roth Capital Investor Meetings 22nd Century Group (Nasdaq: XXII) Announces John J. Miller Joins Its Tobacco Business 22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform 22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company 22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the First Quarter 2022 22nd Century Group (Nasdaq: XXII) Expects VLN® Menthol King Reduced Nicotine Cigarettes To Be Exempted From FDA’s Proposed Ban on Menthol Cigarettes 22nd Century Group (Nasdaq: XXII) Issues Annual Letter to Shareholders 22nd Century Group (Nasdaq: XXII) to Participate in A.G.P./Alliance Global Partner’s Virtual Spring Consumer Cannabis Conference 22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2022 Results on May 5, 2022 First Cigarette That "Helps You Smoke Less" Launches National Pilot in Chicagoland 22nd Century (Nasdaq: XXII) Appoints Dr. Calvin Treat as Chief Scientific Officer FDA Authorized Reduced-Nicotine Cigarette from 22nd Century Group (Nasdaq: XXII) That ‘Helps You Smoke Less’ Obtains Illinois Tobacco Product Listing 22nd Century Group (Nasdaq: XXII) to Host Investor Meetings at Roth Capital Conference March 14-15 22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2021 22nd Century Group Announces South Korea as First VLN® International Market 22nd Century Group Welcomes Dr. Califf as FDA Commissioner, Urges Action on Menthol and Nicotine in Combustible Cigarettes 22nd Century and KeyGene Achieve Breakthrough in Hemp/Cannabis Plant Transformation 22nd Century Secures USDA Organic Certification for Needle Rock Farms 22nd Century Group to Announce Fourth Quarter and Full Year 2021 Results on March 1, 2022 22nd Century Group Supports Upcoming FDA Action Banning Menthol in Highly Addictive Combustible Cigarettes 22nd Century Group Announces First Production of VLN® Cigarettes for Retail Sale 22nd Century Group Appoints James A. Mish to Its Board of Directors 22nd Century Launching the First Reduced Nicotine Cigarette Authorized by the FDA That Helps You Smoke Less 22nd Century Group to Participate in Fireside Chat Events with Alliance Global Partners Equity Analyst Aaron Grey and Cowen Equity Analyst Vivien Azer on Wednesday, January 5, 2022 FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group 22nd Century Ready to Provide Full Commercial Support to New Zealand’s Plan to Reduce Nicotine Content of All Cigarettes 22nd Century Group Announces CFO Transition 22nd Century Group Applauds Califf Nomination as FDA Commissioner 22nd Century to Participate in Cowen and Roth Capital Investor Conferences in November 2021 22nd Century Group Reports Business Highlights and Financial Results for the Third Quarter 2021 22nd Century Group to Host Webcast to Provide Business Update and Discuss Third Quarter 2021 Results 22nd Century Group VP of Regulatory Science to Participate in FDLI Panel in Response to Recent FDA Action on Comprehensive Plan and Reduced Nicotine Mandate 22nd Century to Participate in the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 22nd Century to Participate in September and October 2021 Investor Conferences 22nd Century Group Enters Global Specialty Hops Market 22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors 22nd Century to Present at SNN Network Investor Conference on August 19 22nd Century Group to Ring Nasdaq Closing Bell Today, August 16 22nd Century Group to Begin Trading on Nasdaq on August 16, 2021 22nd Century Group Reports Business Highlights and Financial Results for the Second Quarter 2021 22nd Century Group Secures New Contract Manufacturing Agreements, Expands Distribution Network and Manufacturing Capabilities Ahead of VLN® Launch 22nd Century Group to Host Webcast to Provide Business Update and Discuss Second Quarter 2021 Results 22nd Century Group Adds Strategic Partnerships With Sawatch Agriculture and Folium Botanical for Next-Generation Commercial Hemp/Cannabis Plant Breeding and Commercial Scale-Up 22nd Century Announces Restructuring of Panacea Investment, Expansion of Cannabis Franchise Capabilities 22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives 22nd Century Announces Closing of $40 Million Common Stock Registered Direct Offering Reduced Nicotine Tobacco and Cannabinoid Innovator 22nd Century Group to Be Added to Russell 2000®, Russell 3000®, and Russell Global Indexes 22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise 22nd Century Announces $40 Million Common Stock Registered Direct Offering 22nd Century to Participate in May and June 2021 Investor Conferences 22nd Century VP of Regulatory Science to Present on Health Disparities Caused by Cigarette Addiction at FDLI Annual Conference 22nd Century Group Reports Business Highlights and Financial Results for the First Quarter 2021 22nd Century Group Installs State-of-the-Art Nicotine Testing Equipment to Enhance VLN® Production 22nd Century Group and KeyGene Extend and Expand Plant Research Partnership 22nd Century Group Welcomes Ban on Menthol Cigarettes and Anticipates Further Standards as FDA Commissioner Reports Nicotine Cap on Combustibles “Still on the Table” Congresswoman Gwen Moore Adds Voice to Groundswell of Support for Reducing Nicotine in Cigarettes, Encourages HHS Secretary Becerra to Take Action to Save Lives and End Health Disparities 22nd Century Delivers 3.6 Million Variable Nicotine Content Research Cigarettes for Independent Scientific Studies 22nd Century Group to Host Webcast to Discuss First Quarter 2021 Results 22nd Century Group Issues Annual Letter to Shareholders 22nd Century Fully Prepared to Deliver the Solution as Biden Administration Considers Requirement to Lower Nicotine Level for All Cigarettes Sold in U.S. 22nd Century Stands Fully Prepared to Enable New Zealand Proposal to Advance Nationwide Smoke-Free Action Plan 22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century Becerra Confirmation Boosts 22nd Century’s Position to Disrupt Tobacco Industry 22nd Century Group Receives Additional $3.7 Million from Cash Exercise of Outstanding Warrants 22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020 22nd Century Group to Participate in Investor Conferences in March 2021 22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants 22nd Century Group Secures Exclusive Agreement with CannaMetrix to Accelerate Commercialization of New, Disruptive Hemp/Cannabis Plant Lines and Intellectual Property 22nd Century Group to Host Webcast to Discuss Fourth Quarter and Full-Year 2020 Results 22nd Century Group Provides Business Update Letter from CEO 22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with Commercially Valuable Traits 22nd Century Group to Relocate Headquarters to Buffalo’s Thriving Larkinville District The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes 22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids 22nd Century Receives Order for 3.6 Million New SPECTRUM® Variable Nicotine Cigarettes for U.S. Government-Supported Research 22nd Century Group to Present at 13th Annual LD Micro Main Event Conference 22nd Century’s Vice President of Regulatory Science Publishes Important Public Policy Article 22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference 22nd Century Group to Present at the Virtual Fall Investor Summit on November 17 22nd Century Group Reports Financial Results and Business Highlights for the Third Quarter 2020 22nd Century Group to Host Third Quarter 2020 Webcast and Conduct Quarterly Q&A 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and Policy Conference 22nd Century Group Achieves Breakthrough Technology; Granted New Patent for Reducing Nicotine in Tobacco Plants 22nd Century Group Provides Strategy Update Letter from CEO 22nd Century Appoints Leading Plant Biotechnology Expert Dr. Michael Koganov to Board of Directors 22nd Century Group to Present at the LD Micro 500 Virtual Conference 22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer 22nd Century Group to Host Webcast of 2020 Second Quarter Results 22nd Century Group to Announce First Quarter 2020 Financial Results on May 7, 2020